Donation after circulatory death (DCD) liver transplantation (LT) reportedly yields inferior survival and increased complication rates compared with donation after brain death (DBD). We compare 100 consecutive DCD LT using a protocol that includes thrombolytic therapy (late DCD group) to an historical DCD group (early DCD group n = 38) and a cohort of DBD LT recipients (DBD group n = 435). Late DCD LT recipients had better 1-and 3-year graft survival rates than early DCD LT recipients (92% vs. 76.3%, p = 0.03 and 91.4% vs. 73.7%, p = 0.01). Late DCD graft survival rates were comparable to those of the DBD group (92% vs. 93.3%, p = 0.24 and 91.4% vs. 88.2%, p = 0.62). Re-transplantation occurred in 18.4% versus 1% for the early and late DCD groups, respectively (p = 0.001). Patient survival was similar in all three groups. Ischemic-type biliary lesions (ITBL) occurred in 5%, 3%, and 0.2% for early DCD, late DCD, and DBD groups, respectively, but unlike in the early DCD group, in the late DCD group ITBL was endoscopically managed and resolved in each case. Using a protocol that includes a thrombolytic therapy, DCD LT yielded patient and graft survival rates comparable to DBD LT.
Introduction
One strategy to increase available livers is to use expanded-criteria organs, including those procured from donation after circulatory death (DCD). In 2012, DCD donor livers accounted for only 4.2% and 17.8% of all liver transplantations (LT) in the United States and United Kingdom, respectively (1, 2) . The initial DCD LT US experience yielded inferior graft and patient survival rates compared to traditional donation after brain death (DBD). It also resulted in higher rates of primary nonfunction (PNF) and ischemic-type biliary lesions (ITBL) compared to traditional DBD LT (3) (4) (5) (6) (7) (8) . Consequently, many centers stopped using DCD livers altogether.
Biliary complications occur in up to 53% of recipients after DCD LT (vs. up to 30% in DBD LT (3, 4) ). The severity of biliary lesions ranges from a focal anastomotic stricture (AS) to ITBL, which has a high rate of associated morbidity and mortality (3, 4) . ITBL, defined as the development of intrahepatic strictures, abscesses, hepatic necrosis, or extrahepatic strictures (>1 cm above the biliary anastomosis) in the absence of hepatic artery thrombosis (HAT), occurs in 3-38% of DCD LT (vs. <3% in DBD LT) and is the most feared and frequent cause of DCD allograft failure (3) (4) (5) . ITBL often requires multiple biliary procedures and frequent hospitalizations for cholangitis and often requires retransplantation (8-22%) (6, 9) .
More recently, a few centers reported good results after DCD LT with low rates of ITBL and with graft and patient survival rates comparable to DBD LT (9, 10) . Improved outcomes are attributed to various factors including donor selection, antemortem heparin administration in the donor, minimization of cold ischemia time (CIT), and changes in the implantation technique including injecting tissue plasminogen activator (tPA) into the liver allograft.
Although the etiology of ITBL is not well defined, hypotheses include ischemia-reperfusion injury, microvascular thrombosis, cytotoxic injury, and impaired biliary epithelial regeneration (11) (12) (13) . Centers that report improved results with DCD LT minimize both warm ischemia times (WIT) and CIT and carefully select the potential DCD donor with respect to age, body mass index (BMI), and liver function, among other factors (13) (14) (15) . In 2010, Hashimoto et al (16) hypothesized that microthrombi formation in the peribiliary vascular capillary plexus during the DCD procurement process leads to bile duct ischemia, fibrosis, and subsequent stricture. Based on this hypothesis, several groups started using the thrombolytic agent, tPA. Various approaches to tPA use in DCD LT have included injection into the hepatic artery during allograft procurement prior to cross-clamp (normothermic donor circulation) (17) , at the time of backtable preparation of the allograft (hypothermic conditions) (16) , or during implantation of the allograft after portal reperfusion (18) .
Despite the use of tPA by an increasing number of transplant centers, there are few reports addressing the safety and efficacy of tPA use in DCD LT. We present our experience with 100 consecutive DCD LT using a protocol that includes tPA administration.
Materials and Methods

Study population
This retrospective study was approved by our Institutional Review Board (#2010.180.C). The study included all DCD LT performed at our center from January 2003 through December 2015. In 2010 we introduced a DCD LT protocol that included modifications to the donor operation and administration of tPA during implantation (Table 1) . We compared results of DCD LT using the thrombolytic protocol (late DCD group, n = 100) with our initial DCD experience (early DCD group, n = 38). DCD LT outcomes were compared with those of a DBD LT group performed between January 2013 and March 2016 (n = 435) and matched for surgical history (i.e. patients without a history of significant upper abdominal surgery or dense portal vein thrombosis).
Donor and recipient selection criteria
All DCD donors were controlled (Maastricht type III). No specific DCD donor selection criteria were used, though donor age, BMI, hemodynamic stability, hepatic steatosis, distance from the transplant center, and ischemic times were each considered on an individual basis. Besides of the lack of upper abdominal surgery and Portal Vein Thrombosis, recipient criteria considered included medical comorbidities, BMI, and calculated Model for End Stage Liver Disease (MELD) score.
Organ procurement
Prior to withdrawal of ventilated support, systemic heparin was administered in accordance with local policy. After withdrawal of ventilated support, vital signs and oxygen saturation were recorded every minute. Once circulatory death was declared, a prescribed mandatory waiting time (MWT) (range 2-5 min according to donor hospital or organ procurement organization [OPO] policy) was observed prior to organ recovery.
The donor operation (19) starts with a sharp entry of the abdominal cavity followed by cannulation of the distal aorta or right common iliac artery and cold perfusion (University of Wisconsin solution, UWS, 3 L). Venous decompression is achieved by venting the infrarenal inferior vena cava. The abdominal cavity is filled with slush ice. The first bag of UWS contained 5000 units of heparin and is infused under hand pressure. A midline sternotomy is made and the thoracic aorta is clamped followed by division of the inferior vena cava inside the pericardium. The portal vein system is cannulated and perfused in situ with 2 L of UWS. Once we initiated the protocol in 2010, all DCD liver hepatic veins were flushed on the back table in a retrograde fashion with UWS (%200 mL through each hepatic vein). Donor bile ducts were flushed copiously with UWS.
Ischemia times
Ischemia times were previously described (20, 21) . The donor functional ischemia time was defined as the time from the earliest point when systolic blood pressure dropped <80 mmHg or the arterial oxygen saturation fell <80% until the time cold perfusion began.
Recipient operation and postoperative course
All patients underwent LT using the caval interposition technique without venovenous bypass. Recipients received systemic heparin (1000-3000 U) prior to caval clamping. Cold 5% albumin solution (750 mL) is used to flush the UWS from the liver and runs during the venous implantation. Allografts were reperfused with portal blood after completing the portal venous anastomosis followed by anastomosis of the hepatic artery and subsequent arterial reperfusion. Duct-to-duct biliary reconstruction was used whenever feasible regardless of liver disease etiology; when deemed unfeasible, a Roux-en-Y choledochojejunostomy was performed.
In 2010, we implemented a new DCD protocol that included the following: (1) Syringe injection of 5 mg (2 mL) of verapamil and 2 mg (2 mL) of tPA into the donor hepatic artery immediately after portal vein reperfusion of the liver allograft. These two drugs were allowed to reside in the warm liver while the arterial anastomosis was performed. (2) Postoperatively, once the recipient platelet count rose above 60 000 per microliter and blood urea nitrogen declined below 60 mg/dL, each DCD recipient received 325 mg acetylsalicylic acid (ASA) daily (22) . CIT was minimized by carefully selecting recipients without a history of significant upper gastrointestinal surgery or dense portal vein thrombosis, factors that could potentially complicate and prolong the recipient hepatectomy. Two staff surgeons performed each case, reducing allograft preparation, recipient hepatectomy, and allograft implantation times (Table 1) .
Immunosuppression
All patients received one of two immunosuppression regimens. The standard regimen included methylprednisolone induction (500 mg) followed by a three-drug regimen of tacrolimus, mycophenolate mofetil (MMF), and a prednisone taper. MMF and prednisone were both discontinued 2 months post-LT, leaving patients on tacrolimus monotherapy. Hepatitis C (HCV)-positive patients with MELD scores ≤25 received thymoglobulin induction (3 mg/kg total dose) with steroids given only as pretreatment for thymoglobulin. This was followed by dual therapy with MMF and tacrolimus. MMF was discontinued 2 weeks post-LT, leaving patients on tacrolimus monotherapy (23).
Biliary and vascular outcomes
All endoscopic retrograde cholangiopancreatographies (ERCP), percutaneous transhepatic cholangiograms, magnetic resonance cholangiograms, posttransplant liver ultrasounds, and abdominal computed tomography (CT) scans were reviewed to identify biliary and vascular complications. An ERCP was considered normal if no biliary alterations were identified and no intervention was required. Biliary complications were divided into three categories: AS, anastomotic leak, and ITBL. Vascular ultrasounds, CT scans, and hepatic angiograms were reviewed.
Statistical analysis
Data are expressed as mean AE standard deviation. Student t-test was used for data comparison. Statistical significance was assumed for p < 0.05 with a two-tailed null hypothesis. Survival rates were estimated with the Kaplan-Meier method and comparisons were made with the log-rank test.
Results
Donor characteristics
Compared with our early DCD experience, donors in our late DCD group received more heparin and had shorter mandatory waiting times reflective of changes in local hospital and OPO policies. There were no significant differences in the attributes of DCD donors in the early versus the late groups (Table 1 ). Compared to early DCD LT, late DCD LT were more likely to result from regional donor sharing (51 vs. 11.8%, p = 0.001) and national donor sharing (9 vs. 0%, p = 0.05). Consequently, CITs were significantly longer in the late versus the early DCD group (304.4 AE 92.2 vs. 240.6 AE 45.7 min, p < 0.001) ( Table 2) . Biliary complication rates were similar between early and late DCD groups (23.6 vs. 25%, p = 0.87). A low incidence of ITBL was observed in both DCD groups (5% vs. 3%, p = 0.63), but both DCD groups had significantly higher incidences of ITBL compared with an incidence of 0.5% observed in the DBD group (p = 0.017). All significant adverse events related to biliary complications occurred in the early DCD group: Of the three patients with ITBL, one died of septic complications 3 months post-LT; a second patient died of recurrent HCC and ongoing ITBL, and a third patient was retransplanted and remains alive (Table 5) .
Recipient characteristics
Interestingly, all three cases of ITBL in the late DCD group resolved. Each was diagnosed by ERCP in response to elevated liver function tests (LFTs) and successfully managed endoscopically without retransplantation. Of the three patients who developed ITBL in the late DCD group, one died secondary to HCC recurrence on post-LT day 362. At the time of death, ITBL had resolved, the patient had been stent free for more than 6 months, and the patient's bilirubin was 0.8 mg/dL. A second patient developed one episode of cholangitis and a diagnosis of ITBL made by ERCP. While this patient required multiple ERCPs and biliary stent exchanges, ITBL eventually resolved. Fourteen months post-LT, LFTs normalized, all stents were removed, and this patient has required no further intervention in over 12 months. The third patient with ITBL experienced a similar course. After two episodes of cholangitis and 16 months of sequential ERCPs with stent exchanges, all biliary issues resolved. LFTs normalized and no stent or intervention has been required in more than 4 months (Figure 1 ).
HAT occurred in 3 (7.9%) patients in the early DCD group, in 3 (3%) patients in the late DCD group, and in 2 (0.2%) patients in the DBD group (p = 0.003). While the rate of HAT in both DCD groups was higher than observed in the DBD group, a HAT rate of 3% is similar to published rates of HAT in LTs performed in the United States using DBD donor livers (24, 25) .
Graft and patient survival One-and 3-year graft survival rates were 76.3% and 73.7% in the early DCD group, 92% and 91.4% in the late DCD group, and 93.3% and 88.2% in the DBD group (Figure 2 ). There was no significant difference in graft survival at either 1 or 3 years post-LT between the late DCD group and DBD group (p = 0.24 and 0.62). In contrast, graft survival in the early DCD group was significantly worse at both 1 and 3 years posttransplant One-and 3-year patient survival rates were 86.8% and 84.3% in the early DCD group, 93% and 89.2% in the late DCD group, and 94.7% and 90.1% in the DBD group ( Figure 3 ). Improvements in 1-year and 3-year patient survival rates in the late DCD group compared to the early DCD group did not reach statistical significance (p = 0.25, p = 0.59) and were similar to the DBD group (p = 0.5 and 0.97). First-year death in the early DCD group was attributed to sepsis (two patients), a cardiovascular event (one patient), and HCC recurrence (one patient). In the late DCD group, death within the first year was attributed to sepsis (two patients), recurrent HCC (one patient), and cardiovascular event (two patients). In the DBD group, death occurred from sepsis (11 patients), cardiovascular event (8 patients), HCC recurrence (4 patients), and intraabdominal bleeding (3 patients).
Discussion
Our early experience with DCD LT, while consistent with the experience of others (26, 27) , yielded unacceptable complication and graft loss rates. Rather than abandoning this potential source of organs, we modified our approach to DCD LT with the aim of improving results.
Here we report our experience with the first 100 consecutive DCD liver transplants using a new protocol that includes intra-arterial injection of verapamil and tPA into the allograft after portal reperfusion. Since instituting this protocol, DCD LT patient and graft survival rates are nearly indistinguishable from those observed in DBD LT recipients. Although we observed a higher rate of ITBL in both DCD groups compared to our DBD group, no ITBLrelated graft loss occurred in the late DCD group and each of the three diagnosed cases of ITBL resolved with only endoscopic management. To our knowledge, this is the first report demonstrating that ITBL is a potentially reversible lesion.
Reports of inferior outcomes have dampened enthusiasm for DCD LT in the United States (3, 4, 7) . DCD graft dysfunction is reportedly influenced by prolonged donor hypoxemia, the use of uncontrolled DCD donors, donor WIT >20-30 min, asystole to cross-clamp (acirculatory time) >10 min, liver CIT >8 h, donor age >40-60 years, donor weight >100 kg, recipient allocation MELD scores >25, and the use of DCD livers for retransplantation (7, 21, 28, 29) . While outcomes are multifactorial, the observations presented in this study challenge many of these variables as limits to DCD LT.
The reduction in late DCD donor WIT likely reflects a change in policy for most of our donor hospitals reducing MWT from 5 to 2 min. In addition, livers in the late DCD group received retrograde donor hepatic vein and bile duct flushing. During implantation, recipients received intra-arterial verapamil to decrease potential arterial spasm, adopted from the kidney transplant experience (30, 31) , and intra-arterial tPA. We chose to use tPA in the recipient after the portal vein reperfusion rather than on the back-table to ensure near-normothermic conditions-tPA is less active below 25°C (32,33)-and sufficient concentrations of plasminogen, an essential and rate-limiting substrate for tPA (34, 35) . Our choice of 2 mg was based on our previous experience with tPA in salvage procedures for acute HAT.
Our rationale for use of tPA, that is, the hypothesis that microthrombi form in the peribiliary capillary plexus during the DCD LT process leading to ischemic biliary stricture formation, has been challenged. Several investigators question not only the utility, but also the wisdom of tPA use in DCD LT (12, (36) (37) (38) . Vendrell et al (37) demonstrated hyperfibrinolysis in recipients of uncontrolled DCD donor livers compared with recipients of brain dead donor livers. These investigators did not have access to controlled DCD donor livers, yet the uncontrolled DCD donor liver likely represents a physiologic setting vastly different from that of the controlled DCD liver, a study design weakness recognized by the authors. In that line, Verhoeven et al (38) recently found no evidence of increased microvascular thrombosis from intrahepatic tissue samples from discarded uncontrolled DCD grafts, dismissing the rationale for use of thrombolytic agents in DCD liver transplantation. Other reports frequently cited to dispute the role of microthrombi formation in the development of biliary strictures have predominantly examined the large extrahepatic bile duct and peribiliary vasculature (39, 40) . By contrast, evidence from animal models of DCD LT demonstrates microthrombi formation predominantly in the peribiliary capillaries surrounding predominantly small intrahepatic, not extrahepatic, bile ducts (10, 17, 39, 40 While the pathophysiology of ITBL in DCD LT remains incompletely defined, our goal was to improve clinical outcomes and subsequently utilization of DCD donor livers. Despite liberalizing DCD donor selection criteria during this study period (e.g. high BMI, age >55, increased regional and national imports), we report a very low rate of ITBL in 100 DCD liver transplants using a tPA protocol. Although the use of both systemic heparin and intraarterial tPA during LT has the potential to produce hemorrhage, we did not observe tPA-related systemic bleeding complications. We observed no difference in intraoperative transfusion requirements between any of the three groups studied. Studies of the safety and pharmacokinetics of tPA are based on treatment of stroke, myocardial infarction, and pulmonary embolism including a large bolus (up to 90-mg dose) followed by continuous systemic infusion (42) . First-pass clearance of tPA approaches 80% (42) with an estimated half-life of 2 min. In the case of our protocol, the relatively small single tPA dose (2 mg) infused directly into the donor hepatic artery likely minimized any chance of a significant systemic complication.
The frequency of ITBL observed in our late DCD LT recipients is lower than that reported in other series of DCD LT and compares favorably with some DBD LT series (7, 21, 24) . Nonetheless, both ITBL and HAT occurred in our late DCD group with significantly greater frequency compared to our DBD group. This suggests that not all factors that influence the development of ITBL and HAT in the setting of DCD LT are mitigated by our protocol.
While many factors may contribute to the genesis of complications in DCD LT, the impact of donor and recipient warm ischemia is well described (17, 21, 41, 43) . Of five patients in our DCD cohort who developed ITBL, two-one in the early and one in late group-had prolonged donor ischemic times (>30 min).
Due to the complexity and multiplicity of potential factors that influence the development of complications in DCD LT, we adopted a multifaceted approach to optimize perioperative conditions including the use of tPA, a strategy also implemented by others (17) . Our approach-avoiding long ischemia times, providing full donor anticoagulation, carefully selecting low operative risk recipients, flushing the donor hepatic veins, preemptively treating potential allograft arterial vasospasm, providing recipient systemic heparinization before caval clamping, employing two staff Although some irregularity in the bile ducts persists, there is notable radiographic improvement combined with normalization of serum bilirubin, alkaline phosphatase, and resolution of symptoms. DCD, donation after circulatory death; ERCP, endoscopic retrograde cholangiopancreatography; ITBL, ischemic type biliary lesion; LT, liver transplantation. surgeons for the recipient operation and treating with daily ASA post-LT-yielded results comparable to standard DBD LT. This success has led us to liberalize our thresholds for DCD donor age, hepatic steatosis, and CITs, allowing expanded DCD donor liver utilization beyond our local donor service area (DSA).
We acknowledge the limitations of this retrospective report and lack of randomization in the study design. The improved patient survival observed in the late DCD group versus the early DCD group did not reach statistical significance due to the low incidence of adverse events in both groups, our small sample size, and the high success rate of retransplantation in the early DCD group. It is certainly possible that the lack of a significant reduction in the incidence of ITBL between DCD groups could be explained because the differences in performance between the two DCD groups resulted from increased programmatic experience and implementation of a multifaceted protocol rather than the exclusive influence of the tPA use. The low incidence of ITBL in our late DCD group combined with the lack of a single case of persistent ITBL or a single graft loss due to ITBL collectively support continued use of our protocol with the aim of expanding DCD graft utilization. The potential implications are not insignificant. Even if the number of DCD donors in the United States remained constant, if each DSA achieved the same DCD liver utilization rate as our DSA, US liver transplants would increase by 10%.
Our results, in concert with results recently reported by others (17, 26) , suggest that the stigma attached to DCD LT due to historically observed inferior patient and graft survival rates should be reconsidered. Continued efforts to investigate and improve upon DCD LT are needed and offer the opportunity to meaningfully influence the US liver allograft shortage.
